BCM
INO icon

BlueCrest Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

BlueCrest Capital Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,092
Closed -$118K – 1657
2018
Q1 		$118K Buy
+2,092
New +$113K ﹤0.01% 1338
2017
Q3 		– Sell
-1,135
Closed -$107K – 969
2017
Q2 		$107K Buy
+1,135
New +$97.1K ﹤0.01% 811

Other funds holding INO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlueCrest Capital Management's INO Position: Q2 2018 in Review

BlueCrest Capital Management sold out of Inovio Pharmaceuticals (INO) in Q2 2018, closing a stake of 2,092 shares — an estimated $118K sold.

BlueCrest Capital Management first reported a position in INO in Q2 2017 and held it in 2 quarters. The position peaked at $118K in Q1 2018. 126 funds tracked by Wall St. Rank hold INO as of Q2 2018.

  • BlueCrest Capital Management reported no remaining Inovio Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 2,092 Inovio Pharmaceuticals shares in Q2 2018, an estimated $118K.
  • BlueCrest Capital Management first reported a position in Inovio Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • BlueCrest Capital Management's Inovio Pharmaceuticals position peaked at $118K in Q1 2018.
  • 126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2018.

Based on BlueCrest Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.